Dublin, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The "JointStem Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about JointStem for osteoarthritis in the six major markets. A detailed picture of the JointStem for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the JointStem for osteoarthritis.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JointStem market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.
Drug Summary
JointStem is the world's first stem cell therapy for patients with severe knee OA. It uses autologous adipose tissue-derived mesenchymal stem cells (AdMSC) that improve knee joint function and reduces pain; it also regenerates and improves knee cartilage. Unlike other existing similar drugs for degenerative arthritis, JointStem does not require repetitive injections periodically but requires only one injection of one dose.
It is an innovative therapy without surgery. OA is an irreversible disease and cannot be cured naturally, so an artificial joint replacement is required eventually. But JointStem can delay the deterioration of OA or prevent it, so it is expected that JointStem will be a new therapy with huge benefits at low risks.
JointStem Analytical Perspective
In-depth JointStem Market Assessment
This report provides a detailed market assessment of JointStem for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.
JointStem Clinical Assessment
The report provides the clinical trials information of JointStem for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JointStem dominance.
- Other emerging products for osteoarthritis are expected to give tough market competition to JointStem and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JointStem in osteoarthritis.
- This in-depth analysis of the forecasted sales data of JointStem from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JointStem in osteoarthritis.
Key Questions
- What is the product type, route of administration and mechanism of action of JointStem?
- What is the clinical trial status of the study related to JointStem in osteoarthritis and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JointStem development?
- What are the key designations that have been granted to JointStem for osteoarthritis?
- What is the forecasted market scenario of JointStem for osteoarthritis?
- What are the forecasted sales of JointStem in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
- What are the other emerging products available and how are these giving competition to JointStem for osteoarthritis?
- Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?
Key Topics Covered:
1. Report Introduction
2. JointStem Overview in Osteoarthritis
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. JointStem Market Assessment
5.1. Market Outlook of JointStem in Osteoarthritis
5.2. 6MM, Canada and Korea Analysis
5.2.1. Market Size of JointStem in the 6MM, Canada and Korea for Osteoarthritis
5.3. Country-wise Market Analysis
5.3.1. Market Size of JointStem in the United States for Osteoarthritis
5.3.2. Market Size of JointStem in Germany for Osteoarthritis
5.3.3. Market Size of JointStem in France for Osteoarthritis
5.3.4. Market Size of JointStem in Italy for Osteoarthritis
5.3.5. Market Size of JointStem in Spain for Osteoarthritis
5.3.6. Market Size of JointStem in the United Kingdom for Osteoarthritis
5.3.7. Market Size of JointStem in Canada for Osteoarthritis
5.3.8. Market Size of JointStem in Korea for Osteoarthritis
6. SWOT Analysis
7. Analysts' Views
For more information about this report visit https://www.researchandmarkets.com/r/bo1n0m
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
